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In the present study, we combined the PCR-clamping approach with melting curve analysis using mutant specific hybridisation probes
and wild-type specific peptide nucleic acids (PNAs) to determine the genotypes of the most frequent point mutation in codon 12 of
the proto-oncogene Ki-ras in tissue and plasma samples of patients with pancreatic cancer. The sensitivity of our assay was 1–
5 10
 5. The melting curve analysis of tissue samples of four patients revealed two valine mutations, one none-valine mutation and
one wild-type sequence. Ki-ras alterations were found in 28% of DNAs (18 out of 64) of nonrelated plasma samples of 10 patients
with ductal adenocarcinoma of the pancreas. The valine mutation was the predominantly detected gene alteration (83%). Out of ten
patients investigated, four patients (40%) became positive during clinical observation with respect to Ki-ras mutation. All four patients
exhibited progressive disease and high levels of tumour marker CA 19-9. In conclusion, the one-step procedure discribed may be a
useful clinical tool for analysing Ki-ras point mutations in tissue and plasmas samples. In addition, this method can be adapted for
simultanous detection of multiple mutations and quantitation.
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Pancreatic cancer remains a major cause of death in western
populations. Despite many efforts, little is known about its
aetiology (Malats, 2001). Several risk factors have been implicated:
male gender, black race, cigarette smoking, diabetes mellitus and
meat and fat consumption (Sakorafas et al, 2000; Sternheim et al,
2000; Simon and Printz, 2001).
Ductal adenocarcinoma of the pancreas is a highly aggressive
tumour with an early tendency of spreading to other organs
(Hermanek, 1998). Pancreatic cancer has a poor prognosis. The
median survival is less than 6 months. The overall 5-year survival
of 3% associated with pancreatic cancer is largely a result of
diagnosis late in the course of the disease. Surgical resection
remains the only chance for cure in patients with pancreatic
cancer, but only 15–20% of patients have lesions that are
resectable at the time of diagnosis. Current postresection 5-year
survival rates are approximately 20% (Wong et al, 2001).
Conventional tumour markers, such as CA 19-9, have a high
diagnostic sensitivity (80–90%), but lack a specifity (50–70%) and
are therefore not suited for detecting early tumours (Berndt et al,
1998; Lamerz, 1999; Wenger et al, 1999). More effective screening
techniques are urgently needed to improve the poor prognosis of
the disease (Mizumoto and Tanaka, 2002).
Pancreatic cancer is among the best-described genetic diseases
(Hilgers and Kern, 1999). The development and growth of
pancreatic adenocarcinoma involves oncogene activation, loss
of tumour suppressor gene function and overexpression of
receptor-ligand systems (Goggins et al, 1999; Efthimiou et al,
2001; Shi et al, 2001). The Ki-ras oncogene is one of the three
members of the human ras gene family that code for the highly
related 21-kDa proteins with guanosine triphosphatase (GTPase)
activity. Naturally occurring mutations in the Ki-ras gene
have been localised to codon 12 (most frequently), 13 and 61.
Owing to an associated inappropriate stimulation signal, the
mutant ras transmits a constitutive growth signal to the nucleus
(Gansauge et al, 1996; Olson and Marais, 2000). The incidence of
ras gene mutations varies among different kinds of tumours, but
was found mutated predominantly in pancreatic adenocarcinomas
with a frequency of 80–90% (Sirivatanauksorn et al, 1998; Ghaneh
et al, 2002).
Gene alterations of the ras type can be used as molecular
markers to screen for the presence of neoplastic cells in different
clinical specimens. Enriched PCR methods are able to discriminate
mutant from wild-type alleles and also provide a high degree of
sensitivity to detect mutant alleles in a large excess of normal DNA.
Two PCR-based techniques have been most commonly used: ASA-
PCR (allele-specific amplification), which is restricted to the
analysis of individual codon-specific mutations and requires
several allele-specific oligonucleotides, and the time-consuming
RFLP-PCR (restriction fragment length polymorphism), which
bears an increasing risk of Taq polymerase-born infidelity (Weber,
1990; Kahn et al, 1991; Takeda et al, 1993; Jacobson and Mills,
1994; Mora et al, 1998).
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peptide nucleic acids (PNAs) has been exploited to design novel
protocols (PCR-clamping). PNAs are none extendable oligonucleo-
tides where the ribose-phosphate backbone is completely replaced
by (2-aminoethyl)-glycine units linked by amide bonds. These
synthetic oligomers bind with higher thermal stability to
complementary nucleic acids than DNA and RNA. On the other
hand, the PNA/DNA duplex is significantly destabilised in the case
of single-base mismatch (Ørum et al, 1993; Ratilainen et al, 1998).
In PNA-mediated PCR clamping, PNA oligomers suppress
amplification of the wild-type sequence confined by a pair DNA
oligonucleotide primers (competetive clamping) because PNA
oligomers are no substrate for DNA polymerases. In the case of a
single-base mismatch, the DNA/PNA duplex is destabilised, which
allows strand elongation from bound DNA oligomer to proceed,
resulting in the detection of PCR fragments, most of which
harbour the variant allele, and the suppression of wild-type
genomic sequences during amplification, respectively. This
approach has been described for the detection of Ki-ras and p53
point mutations (Thiede et al, 1996; Behn et al, 2000).
Analysis of PCR products via mutation-specific hybridisation
probes guarantees the most specific measurement of amplified
target sequences. Hybridisation probes consists of two terminally
fluorescent-labelled oligomers. Only after binding to the target
sequence in close proximity, fluorescence resonance energy
transfer (FRET) occur (Lay and Wittwer, 1997) and the real-time
fluorescence can be monitored. Hybridisation probes are further-
more suitable for experiments in which the amplification products
formed are subsequently quantified using the evaluation software.
The combination of detection by internal hybridisation probes and
subsequent melting curve analysis expands the spectrum to
include mutation analysis by rapid genotyping. One mismatch
only, due to a single point mutation, between the internal
hybridisation probes and their target sequences, can drastically
change the melting temperature of the bound probe (Lyon, 2001).
In a recent study, the PNA-mediated PCR clamping method was
combined with on-line detection for c-kit proto-oncogene point
mutations (Sotlar et al, 2003).
In the present study, we combined the PCR-clamping approach
using a wild-type PNA (17-mer) with real-time PCR using mutant-
specific hybprobes in single closed LightCycler capillaries. As a
preliminary study, plasma and tissue samples of patients with
pancreatic cancer were analysed with respect to point mutations in
codon 12 of the Ki-ras proto-oncogene by melting point analysis.
MATERIAL AND METHODS
Patients
A total of 64 sera from 10 patients (seven male, three female) with
pancreatic carcinoma (resectable and nonresectable) were analysed
for Ki-ras mutation. In addition, four tissue samples from
nonrelated pancreatic tumours were analysed for Ki-ras mutation.
Cell lines
Cells of the cell line SW 480 (colon carcinoma) harbouring a
homozygous Ki-ras codon 12 mutation were cultured in RPMI
1640 medium (50ml culture flask) supplemented with 10% (vv
 1)
heat-inactivated fetal calf serum and 100mgml
 1 streptomycin
(humidified atmosphere, 5% CO2,3 7 1C). Adherent cells were
trypsinised and washed once with PBS solution (phosphate-
buffered saline).
DNA extraction from the plasma
Blood samples (9ml) were withdrawn from a peripheral vein
and placed in tubes containing EDTA. The collected samples
were centrifuged at 1500r.p.m. for 10min (Minifuge RF,
Heraeus, Hanau, Germany). Plasma was stored at  201C until
further use. DNA was extracted from plasma with QIAamp
spin columns (QIAamp DNA Mini Kit, Qiagen, Hilden,
Germany) according to the manufacturer’s instruction. Incuba-
tion with proteinase K was performed for 10min at 681C.
Extracted DNA from 200ml of plasma was eluted with 50ml and
stored at  201C.
Isolation of DNA from paraffin-embedded tissue
Tumour tissues were obtained at surgery and fixed with paraffin.
DNA was extracted from tissue with QIAamp spin columns
(QIAamp DNA Mini Kit) according to the manufacturer’s
instruction. In brief, not more than 25mg of paraffin-embedded
tissue was placed into a 2ml microcentrifuge tube. Removal of
paraffin was ensured by adding and mixing 1200ml xylene. After
centrifugation at full speed for 5min at room temperature,
the supernatant was carefully removed and 1200ml of ethanol
(96–100%) was added to the pellet. The mixture was centrifuged
at full speed for 5min at room temperature; afterwards, the
ethanol was carefully removed. To remove residual xylene
completely, the procedure was repeated. The open microcentri-
fuge tube was incubated at 371C for 10–15min until the ethanol
had evaporated and the DNA was extracted was with QIAamp
spin columns (QIAamp DNA Mini Kit, Qiagen, Hilden,
Germany) according to the manufacturer’s instruction. Lysis in
the presence of proteinase K was overnight at 561C. AL (200ml)
buffer was added and mixed. DNA was eluted with 100mlo fA E
buffer and stored at  201C.
Isolation of DNA from SW480 cells
Cells were resuspended in 200ml of PBS solution. After adding
20ml proteinase K and 200ml AL buffer, the mixture was incubated
at 561C for 10min. DNA extraction was continued as with tumour
tissue (see above).
Real-time PCR and melting curve analysis
Real-time PCR was performed in a final volume of 20ml containing
10mM TRIS-HCl pH 8.3, 50mM KCl, 3.75mM MgCl2, 125mM of
each desoxynucleotide triphospate (Invitrogen, Carlsbad, USA),
1mM of primer Ki-ras F (50-AAG GCC TGC TGA AAA TGA CTG-30)
and 1mM Ki-ras R (50-GGT CCT GCA CCA GTA ATA TGC A-30),
0.3mM hybridisation probe Ki-ras FL (donor) labelled on its 30-end
with fluorescein (50-CGT CCA CAA AAT GAT TCT GAA TTA GCT
GTA TCG TCA AGG CAC T-F-30) and 0.3mM Ki-ras LC (acceptor)
labelled on its 50-end with the fluorescence dye LightCyclert-Red
640 (50-LC Red640-TTG CCT ACG CCA ACA GCT CCA A-P-30),
2.5mM PNA 17 mer (50-CCT ACG CCA CCA GCT CC-30), Protein
Amplifly and 1.25U of Platinum Taq DNA polymerase (Invitro-
gen). After an initial denaturation step at 951C for 3min, 45 cycles
were performed with each cycle consisting of: denaturation at 951C
for 10s, PNA annealing at 761C for 7s, annealing of the primers
and probes at 601C for 15s and elongation at 721C for 20s. PCRs
were carried out on the LightCycler Instrument (Roche Diagnos-
tics, Mannheim, Germany).
Melting curve analysis was performed at steadily increasing
temperature from 40 to 851C with a transition rate of 0.31Cs
 1.
Fluorescence data obtained were analysed using the LightCycler
software (software version 3.5, Roche Diagnostics).
Enriched BstNI RFLP/PCR
Enriched BstNI RFLP/PCR was confirmed as described elsewhere
(Mora et al, 1998). Digestion of the amplified products with the
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was performed according to the manufacturer’s instruction. After
two rounds of PCR (heminested PCR) and digestions of the
amplified DNA, all PCR products were electrophoresed in a 3%
agarose gel (low melting point agarose) and the mutant allele
(143-bp band) and the wild-type allele (114-bp band) was
visualised by ethidium bromide staining (0.5mgml
 1). All
synthetic oligonucleotides used were purchased from TIB Molbiol
(Berlin, Germany).
RESULTS
Determination of interassay variability and optimisation
of PNA concentration
For detection of the hot spot point mutation of the Ki-ras proto-
oncogene at codon 12, we used PNA-mediated PCR-clamping and
real-time PCR with mutant-specific hybridisation probes. The
relative positions of primers, hybridisation probes and PNA are
shown in Figure 1 (Genbank accession no. K01519; nucleotid
positions 1–164). For PNA and hybprobes, the antisense strand
was chosen due to the lower purine content to reduce mismatches.
After optimising the PCR conditions, the interassay variability of
the melting temperatures was determined. For wild-type and
valine-mutated DNA, the variability was 68.01C70.8 (n¼15) and
71.21C70.8 (n¼15), respectively, and therefore allows precise
discrimination of wild-type and mutant DNA by melting point
analysis.
In appropriate clinical samples the proportion of malignant or
premalignant to normal cells is extremely low. As shown in
Figure 2, the melting points of 100pg of mutant DNA extracted
from SW 480 colon carcinoma cells in the presence of 1mg of wild-
type DNA (1:10000) were not detectable (curve 2 and 4). However
now, in the presence of PNA, the wild-type-specific peak
disappears and the mutant allele was detectable in a 1:10000
Intron 1
ki-ras anchor 12val sensor
PNA 17 ki-ras R 
ki-ras F
Exon 1  Codon 12
Figure 1 Relative positions and orientations of PCR primers (ki-ras F; ki-
ras R), hybridisation probes (12val sensor; ki-ras anchor) and the wild-type
peptide nucleic acid (PNA-17) for detection of codon 12 mutation of the
Ki-ras proto-onkogene (Genbank accession no. K01519; nucleotid positions
1–164).
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Figure 2 Titration of PNA concentrations for complete suppression of amplification of 1mg of wild-type DNA (WT DNA; human placenta DNA) in the
presence of 100pg of mutated DNA (10000:1) extracted from cells of the colon carcinoma cell line SW 480, which bears the codon 12 mutation of the Ki-
ras proto-oncogene (GGT to GTT; glycine to valine) homozygous. After rapid cycle amplification of the DNA in the presence of the valine mutation-specific
hybridisation probes, the melting curves were analysed by the LightCycler software (version 3.5). Temperature transition rate was 0.31Cs
 1. 1: non template
control (NTC); 2: 1mg wild-type (WT) DNA without PNA; 3: 100pg Val DNA without PNA; 4: 1mg WT DNA/100pg Val DNA without PNA; 5–8: 1mg
WT DNA/100pg Val DNA each with raising concentrations of PNA as indicated. PCR experiments were performed twice.
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amplification, raising amounts of PNA were used. In the presence
of a PNA concentration of 2.5mM in the assay (curve 8), only the
mutant-specific peak was observed comparable to curve 3 of the
mutation-specific peak. Lower concentrations of PNA show a weak
shoulder at the wild-type-specific melting temperature (curves 5–
7; arrow), indicating incomplete suppression of the wild-type DNA
amplification. Under these conditions, quantification of mutant
DNA is impossible. It should be noted that higher PNA
concentrations lead to a decrease of the efficiency of DNA
amplification and therefore lowers fluorescence intensities (data
not shown).
Determination of the sensitivity of the assay and
quantification of mutated DNA
To determine the sensitivity of our assay, serially an equivalent of
2–20000 tumour cells of the colon carcinoma cell line SW 480,
which bear the codon 12 mutation glycine (GGT) to valine (GTT)
homozygous, were mixed each with 2000000 normal peripheral
blood cells from a healthy subject. After DNA extraction, one-tenth
of the eluted DNA was analysed. As seen in Figure 3A, an
equivalent of two mutated cells can be detected in the presence of
genomic DNA of an equivalent of 200000 wild-type cells, which
corresponds to a sensitivity of 1 to 5:100000. The melting
temperatures for wild-type and mutated DNA are 68.6 and 71.21C,
respectively. Additionally, the same dilution experiments were
performed using enriched BstNI RFLP/PCR (Mora et al, 1998).
After gel electrophoresis of the amplified products, the mutant
allele (143-bp band) and wild-type allele (114-bp band) could be
visualised after ethidium bromide staining. The detection limit of
the mutation was 10
 3 (data not shown). Another favourite
advantage of our real-time PCR technology is the quantification of
mutated DNA simultaneously, if the amplification of the wild-type
DNA was completely suppressed as seen in Figure 3A. After
analysing the crossing points by the LightCycler software
(Figure 3B, upper panel), the regression line was linear
(slope¼ 2.878; r¼ 0.99) in the range of 4–40000 copy numbers
of mutated DNA in the background of 400000 copies of wild-type
DNA (Figure 3B, lower panel).
Genotyping of pancreatic tissue samples
Melting point analysis of amplification products was performed on
five tissue samples of four patients. Patient no. 2 and 3 (Figure 4,
curves 4 and 5) revealed a melting temperature of 72.11C
corresponding to a valine mutation in codon 12 of the DNA.
Two different tissue samples (A and B) of patient no. 4 (Figure 4,
curves 6 and 7) showed a melting point of 68.51C representing a
mutation other than valine. Further verification of this point
mutation was not done. Complete suppression of amplification of
wild-type DNA is demonstrated in Figure 4 (curve 16) using a ratio
of mutant to wild-type DNA of 1 to 10000. In the presence of the
wild-type specific PNA, an additional tissue sample of patient no. 1
(Figure 4, curve 3) was analysed and no fluorescence signal was
detected, indicating the wild-type allele. All DNAs were tested by
amplification without PNA, first.
Genotyping of plasma samples of patients with pancreatic
cancer
Adequate amounts of DNA were extracted from 64 plasma samples
of 10 patients (seven male, three female) with pancreatic cancer
and three healthy subjects. Blood samples were obtained at least
monthly over a period up to 13 months. To determine the amount
of DNA per assay, real-time PCR was performed in the absence of
PNA (data not shown). Owing to the low amount of extractable
plasma DNA, we were able to use approximately 0.5ng per assay.
The PCR method using PNA-mediated PCR-clamping and
hybridisation probes showed that the plasma samples of the three
healthy control cases were negative for Ki-ras mutations as no
fluorescence signals were detectable in the presence of wild-type-
specific PNA. Ki-ras alterations were found in DNAs from 18 out of
64 (28%) plasma samples of four out of 10 patients with ductal
adenocarcinoma of the pancreas. The mutation from glycine to
valine was the predominantly detected gene alteration (15 out of
18; 83%). Other mutations were not further analysed.
Data synopsis of patients investigated is summarised in Table 1.
The median was 11.5 months (5–83 months) after diagnosis. Two
patients were suitable for surgical therapy. Among all patients
metastases were detectable during tumour staging.
Time course analysis of the different clinical samples is shown in
Table 2 in context with serum levels of the tumour marker CA 19-
9, pharmacological treatments and tumour imaging.
Out of the 10 patients investigated, four patients became positive
during clinical observation with respect to Ki-ras mutation (nos.
11, 34, 39, 43). In all these cases, the mutated DNA was steadily
detected until death of the patients in association with tumour
progression and raising CA 19-9 serum levels (410
4Uml
 1). The
altered Ki-ras gene was not detected in patient no. 40, while CA 19-
9 level was slightly elevated.
Three patients (nos. 13, 16, 38) show raising tumour marker
values along with progressive disease, but no mutation was
detectable in plasma samples. Patients nos. 29 and 37 showed
progressive disease, while CA 19-9 values were low and no Ki-ras
gene alterations were found.
DISCUSSION
Our aim was to establish an assay for the detection of the hot spot
mutation in codon 12 of the Ki-ras gene in plasma samples using
PNA-mediated PCR-clamping and mutant-specific hybridisation
probes. In contrast to Thiede et al (1996), where in case of mutant
DNA the PCR primer outcompete the wild-type specific PNA, we
used wild-type PNA (17-mer) and mutant-specific fluorescent-
labelled hybridisation probes. Owing to the higher thermal
instability of mutant DNA and wild-type-specific PNA hybrids,
the detected fluorescence signal corresponds to the amplified
mutant DNA and can be analysed by subsequent melting curve
analysis.
Ki-ras mutations were analysed in a multitude of clinical
specimens like fine-needle aspirates, stool, pancreatic and
duodenal juice, blood cells, serum and plasma (Minamoto et al,
2000) with high specificity (up to 100%) and a wide spectrum of
sensitivities in the range of 27–100% (Mulcahy et al, 1998; Castells
Figure 3 Titration of assay sensitivity. (A) Sensitivity of melting point analyses using mutant-specific hybridisation probes and wild-type specific PNA.
Peripheral blood cells from a healthy donor (HD) and SW 480 colon carcinoma cells, which bear the valine mutation homozygous (Val), were mixed as
indicated and DNA was extracted by spin column technology. After rapid cycle amplification of the DNA in the presence of the valine mutation-specific
hybridisation probes, the melting curves were analysed by the LightCycler software (version 3.5). Temperature transition rate was 0.31Cs
 1. 1: nontemplate
control (NTC); 2: WT DNA without PNA; 3: 2 10
4 SW480þ2 10
5 WT; 4: 2 10
3 SW480þ2 10
5 WT; 5: 2 10
2 SW480þ2 10
5 WT; 6:
2 10
1 SW480þ2 10
5 WT; 7: 2 10
0 SW480þ2 10
5 WT. (B) Quantification of Val DNA in the presence of WT DNA. Serial diluted mixtures of
constant amounts of wild-type DNA and varying amounts of Val DNA from cells as indicated (see Figure 3A) were plotted against Ct values (threshold
cycle). Slope, r value and regression line are shown. PCR experiments were performed twice.
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set al, 1999; Li et al, 2004). Owing to the retroperitoneal position of
the pancreas, tissue samples are difficult to obtain. Therefore,
analysis of clinical samples easy and noninvasive to obtain like
plasma would make molecular diagnosis easier, especially in
earlier stages of pancreatic cancer and follow-up investigations.
The origin of mutated plasma DNA of patients with malignant
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sneoplasm is uncertain but due to the same gene alterations as the
primary tumour it is likely that lysed tumour cells are the origin of
naked DNA (Castells et al, 1999). The analysis of tumour cells in
peripheral blood is difficult because of the rareness of neoplastic
cells. Furthermore, large amounts of nonmutated leucocytes mask
the vestiges of mutated cells.
We restricted our point mutation analysis to one of the
preferred glycine (GGT) to valine (GTT) variant as described in
literature (Anker et al, 1997), but our method allows the detection
of the other gene alterations at codon 12 (aspartic acid,
arginine and cysteine), too. The applicability of this method,
first of all the correlation of detected gene mutations with
clinicopathological findings, was evaluated by subsequent
time course analysis of circulating non-cell-associated DNA in
peripheral blood of patients with pancreatic cancer. The
occurrence of Ki-ras gene mutations in primary panc-
reatic tumours is well known from literature (Tada et al, 1993;
Sorenson et al, 1994; Mulcahy et al, 1998). We also could detect
Ki-ras gene mutations in selected tissue samples of the pancreas
using our assay.
The sensitivity of our assay revealed a value of 0.001% being
the highest compared with other methods for genotyping like
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Figure 4 Detection of Ki-ras point mutations in tissue samples. DNA from paraffin-embedded tissue samples of four different patients with pancreatic
cancer were extracted by spin column technology after overnight digestion with proteinase K. After rapid cycle amplification of the eluted DNA in the
presence of the valine mutation-specific hybridisation probes and wild-type-specific PNA, the melting curves were analysed by the LightCycler software
(version 3.5). Temperature transition rate was 0.31Cs
 1 in the range of 40–951C. PCR experiments were performed twice. Melting temperatures (Tm):
wild-type DNA: 69.51C, valine DNA 72.11C and unknown mutation 68.51C. 1: Nontemplate control (NTC); 2: 1mg wild-type DNA (WT) without PNA;
3–7: tissue samples of patients. From patient no. 4, two different samples (4A and 4B) were analysed; 16: 100pg Val DNA/1mg WT DNA in the presence
of PNA.
Table 1 Patients and incidence of Ki-ras mutations in plasma DNA
No. Sex Age (years) Tumour site Tumour stage Histological type Surgery Survival WT Mut
11 M 67 NA IVb DAC No 9 2 5
13 M 81 Head Metastases DAC No 6 5 0
16 M 70 Head IVb NA No 35 10 0
29 M 51 Head Metastases DAC (moderate) No 5 3 0
34 M 50 Head Metastases DAC (poorly) No 8 3 3
37 F 69 Head T2, N1, M1 NA No 23 9 0
38 F 57 Head Metastases DAC (moderate) No 6 4 0
39 M 59 Head Metastases DAC (moderate) Yes 83 1 1
40 F 71 Head T3, N1, M1 DAC (moderate/poorly) Yes 43 9 0
43 M 52 Head Metastases DAC (moderate) No 14 0 9
DAC¼ductal adenocarcinoma; NA¼data not available; Survival¼survival in months after diagnosis; WT¼wild-type (number of samples); Mut¼mutation (number of
samples).
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1.0–0.001% (Jacobson and Mills, 1994; Rhodes et al, 1997).
Furthermore, the rapid cycle PCR enables quantification of the
mutant DNA simultaneously if the fluorescence signal of the wild-
type DNA is completely suppressed by binding of the PNA.
Quantification of mutant-type Ki-ras gene in plasma samples is
inappropriate due to the low amount of DNA and the absence of
cellular equivalents which allows the quantification of single copy
genes as a reference. This method allows a very fast detection of
Ki-ras point mutations (B1h) after DNA preparation from clinical
samples. As no post-PCR handling is necessary, the possibility of
contamination is minimised, which contributes to reduce false
positive results.
While all previous studies only analysed one sample per
individual after diagnosis of pancreatic cancer, we present a
preliminary study of time course analysis of Ki-ras gene
alterations. Thus, occurrence of mutations in samples analysed
in our study can hardly be compared with incidences found by
other investigators (Mulcahy et al, 1998; Castells et al, 1999;
Dianxu et al, 2002; Maire et al, 2002). The percentages of plasma
samples with mutated Ki-ras gene found to date in the existing
studies differ in a wide range of 27–81%, which might reflect
collection of samples at different tumour stages and various
sensitivities of the assays for detection of Ki-ras point muta-
tions. Dianxu et al (2002) tested 37 of 41 patients (90.2%) with
pancreatic cancer positive when plasma Ki-ras mutation analysis
was combined with elevated CA 19-9 serum levels (437Uni-
tsml
 1). In our study, we detected Ki-ras mutant alleles only
in four out of 10 patients with high CA 19-9 levels. These
differences might be due to different sensitivities of the
detection methods, even though the sensitivity of our method
was the highest compared to the others. In general, more clinical
samples of patients with pancreatic cancer, chronic pancreatitis
and healthy individuals have to be analysed for determination
of sensitivity, specificity, negative and positive predictive values of
the assay presented in this study. Owing to the limited number
of patients analysed, a correlation of the detectable Ki-ras
mutations with clinicopathological findings and pharmacological
treatments is certainly prematurely, but we can demonstrate
the potential of the rapid cycle PCR in the presence of wild-type
Table 2 Association with clinicopathological findings
Months after first sample
Patient 0 1 2 3 4 5 6 7 8 9 10 11 12 13
No. 11
FS 3
Ex 10
Gly Gly Val NA Val Val Val Val ’Ki-ras status in plasma
2654 2706 5288 410
4 8077 NA 410
4 ’CA 19-9 level in serum (Uml
 1)
GFF GFF Tax Tax Tax Tax Tax Tax ’(Chemo-) therapy
NC PD ’Imaging
No. 13
FS 0
Ex 7
Gly NA Gly NA Gly Gly Gly
6879 NA 698 654 2254 410
4 410
4
Gem Gem Gem Gem Gem Gem OFF
PR PD
No. 16
FS 22
Ex 35
Gly NA Gly NA Gly NA Gly Gly Gly Gly Gly NA Gly Gly
109 62 43 NA 45 90 NA 191 340 426 1948 NA 4216 NA
OFF OFF OFF OFF OFF OFF OFF OFF OFF OFF OFF OFF Gem Gem
NC NC PD
No. 29
FS 2
Ex 5
Gly Gly Gly NA
1N A 9 3 2
Gem OFF OFF
PD PD
No. 34
FS 1
Ex 8
Gly NA Gly Gly Mut Mut Mut
5916 2291 4169 410
4 410
4 410
5 NA
Gem Gem Gem Gem Gem OFF OFF
PR PD
No. 37
FS 11
Ex 23
Gly NA Gly NA Gly Gly Gly Gly Gly Gly Gly
7 N A1 3N A2 8 3 7 N A4 1 5 0 5 25 6
Tax Tax Tax Tax Tax Tax Tax Tax Tax Tax Tax
No. 38
FS 1
Ex 5
Gly Gly Gly Gly
410
6 410
6 NA 410
6
Gem Gem OFF OFF
PD
No. 39
FS 82
Ex 83
Gly Val
410
4 410
4
Gem Gem
PD
No. 40
FS 31
Ex 43
Gly NA NA Gly NA Gly Gly Gly Gly Gly Gly NA Gly
NA NA 309 NA NA 464 NA 179 NA NA 218 NA 251
Gem Gem Gem Gem OFF Tax Tax Tax
PD
No. 43
FS 1
Ex 14
Val NA NA Val Val Val Val Val Val Val Val NA NA
677 NA 434 1365 2116 5231 883 446 544 1506 410
4 410
4
GFF GFF GFF GFF GFF Tax Tax Tax Tax Tax Tax
PD PR
FS¼time of 1st collected sample after diagnosis (in months); Ex¼death in months after collection of the 1st sample; NA¼no data available; Gly¼glycine (wild type);
Val¼valine (mutation); Mut¼mutation different from valine; GFF¼gemcitabine+5-fluorouracil+folinic acid; Gem¼gemcitabine mono; Tax¼taxol; OFF¼oxaliplatin+5-
fluorouracil+folinic acid; NC¼no change; PD¼progressive disease; PR¼partial regression.
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sPNA and mutation-specific hybridisation probes for detection of
point mutations.
We could identify Ki-ras-mutated alleles by this rapid real-time
PCR at late stages of carcinogenesis very well and may contribute
to therapeutic regimes and clinical practice.
ACKNOWLEDGEMENTS
We thank Monika Seifert for excellent technical work, our study
nurses who cared for patients and Miriam Peet for carefully
reading the manuscript.
REFERENCES
Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XQ, Stroun
M, Mulcahy HE, Farthing MJ (1997) K-ras mutations are found in DNA
extracted from the plasma of patients with colorectal cancer. Gastro-
enterology 112(4): 1114–1120
Behn M, Thiede C, Neubauer A, Pankow W, Schuermann M (2000)
Facilitated detection of oncogene mutations from exfoliated tissue
material by a PNA-mediated ‘enriched PCR’ protocol. J Pathol 190(1):
69–75
Berndt C, Haubold K, Wenger F, Brux B, Muller J, Bendzko P, Hillebrand T,
Kottgen E, Zanow J (1998) K-ras mutations in stools and tissue samples
from patients with malignant and nonmalignant pancreatic diseases. Clin
Chem 44(10): 2103–2107
Castells A, Puig P, Mora J, Boadas J, Boix L, Urgell E, Sole M, Capella G,
Lluis F, Fernandez-Cruz L, Navarro S, Farre A (1999) K-ras mutations in
DNA extracted from the plasma of patients with pancreatic carcinoma:
diagnostic utility and prognostic significance. J Clin Oncol 17(2): 578–584
Dianxu F, Shengdao Z, Tianquan H, Yu J, Ruoqing L, Zurong Y, Xuezhi W
(2002) A prospective study of detection of pancreatic carcinoma by
combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas
25(4): 336–341
Efthimiou E, Crnogorac-Jurcevic T, Lemoine NR (2001) Pancreatic cancer
genetics. Pancreatology 1(6): 571–575
Gansauge S, Gansauge F, Beger HG (1996) Molecular oncology in
pancreatic cancer. J Mol Med 74(6): 313–320
Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP (2002) Molecular
prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg
9(1): 1–11
Goggins M, Kern SE, Offerhaus JA, Hruban RH (1999) Progress in cancer
genetics: lessons from pancreatic cancer. Ann Oncol 10(Suppl 4): 4–8
Hermanek P (1998) Pathology and biology of pancreatic ductal adeno-
carcinoma. Langenbecks Arch Surg 383(2): 116–120
Hilgers W, Kern SE (1999) Molecular genetic basis of pancreatic
adenocarcinoma. Genes Chromosomes Cancer 26(1): 1–12
Jacobson DR, Mills NE (1994) A highly sensitive assay for mutant ras genes
and its application to the study of presentation and relapse genotypes in
acute leukemia. Oncogene 9: 553–563
Kahn SM, Jiang W, Culbertson TA, Weinstein IB, Williams GM, Tomita N,
Ronai Z (1991) Rapid and sensitive nonradioactive detection of mutant
K-ras genes via ‘enriched’ PCR.amplification. Oncogene 6: 1079–1083
Lamerz R (1999) Role of tumour markers, cytogenetics. Ann Oncol
10(Suppl 4): 145–149
Lay MJ, Wittwer CT (1997) Real-time fluorescence genotyping of factor V
Leiden during rapid-cycle PCR. Clin Chem 43(12): 2262–2267
Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet
363(9414): 1049–1057
Lyon E (2001) Mutation detection using fluorescent hybridization probes
and melting curve analysis. Expert Rev Mol Diagn 1(1): 92–101
Maire F, Micard S, Hammel P, Voitot H, Levy P, Cugnenc PH, Ruszniewski
P, Puig PL (2002) Differential diagnosis between chronic pancreatitis and
pancreatic cancer: value of the detection of KRAS2 mutations in
circulating DNA. Br J Cancer 87(5): 551–554
Malats N (2001) Gene–environment interactions in pancreatic cancer.
Pancreatology 1(5): 472–476
Minamoto T, Mai M, Ronai Z (2000) K-ras mutation: early detection in
molecular diagnosis and risk assessment of colorectal, pancreas, and
lung cancers – a review. Cancer Detect Prev 24(1): 1–12
Mizumoto K, Tanaka M (2002) Genetic diagnosis of pancreatic cancer.
J Hepatobiliary Pancreat Surg 9(1): 39–44
Mora J, Puig P, Boadas J, Urgell E, Montserrat E, Lerma E, Gonza ´lez-Sastre
F, Lluı ´s F, Farre ´ A, Capella ´ G (1998) K-ras gene mutations in the
diagnosis of fine-needle aspirates of pancreatic masses: prospective study
using two techniques with different detection limits. Clinical Chem 44:
2243–2248
Mulcahy HE, Lyautey J, Lederrey C, qi Chen X, Anker P, Alstead EM,
Ballinger A, Farthing MJ, Stroun M (1998) A prospective study of K-ras
mutations in the plasma of pancreatic cancer patients. Clin Cancer Res
4(2): 271–275
Olson MF, Marais R (2000) Ras protein signalling. Semin Immunol 12(1):
63–73
Ørum H, Nielsen PE, Egholm M, Berg RH, Buchardt O, Stanly C (1993)
Single base pair mutation analysis by PNA directed PCR clamping. NAR
21: 5332–5336
Ratilainen T, Holmen A, Tuite E, Haaima G, Christensen L, Nielsen PE,
Norden B (1998) Hybridization of petide nucleic acid. Biochemistry 37:
12331–12342
Rhodes CH, Honsinger C, Porter DM, Sorenson GD (1997) Analysis of the
allele-specific PCR method for the detection of neoplastic disease. Diagn
Mol Pathol 6: 49–57
Sakorafas GH, Tsiotou AG, Tsiotos GG (2000) Molecular biology of
pancreatic cancer; oncogenes, tumour suppressor genes, growth factors,
and their receptors from a clinical perspective. Cancer Treat Rev 26(1):
29–52
Shi X, Friess H, Kleeff J, Ozawa F, Buchler MW (2001) Pancreatic cancer:
factors regulating tumor development, maintenance and metastasis.
Pancreatology 1(5): 517–524
Simon B, Printz H (2001) Epidemiological trends in pancreatic neoplasias.
Dig Dis 19(1): 6–14
Sirivatanauksorn V, Sirivatanauksorn Y, Lemoine NR (1998)
Molecular pattern of ductal pancreatic cancer. Langenbecks Arch Surg
383(2): 105–115
Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL (1994)
Soluble normal and mutated DNA sequences from single-copy genesin
human blood. Cancer Epidemiol Biomarkers Prev 3(1): 67–71
Sotlar K, Escribano L, Landt O, Mohrle S, Herrero S, Torrelo A, Lass U,
Horny HP, Bultmann B (2003) One-step detection of c-kit point
mutations using peptide nucleic acid-mediated polymerase
chain reaction clamping and hybridization probes. Am J Pathol 162(3):
737–746
Sternheim ET, Voigt J, Kaspar W, Dippold WG (2000) Pancreatic
carcinoma. Internist (Berl) 41(9): 848–854, 856–859
Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, Sninsky JJ (1993)
Detection of ras gene mutations in pancreatic juice and peripheral blood
of patients with pancreatic adenocarcinoma. Cancer Res 53(11): 2472–
2474
Takeda S, Ichii S, Nakamura Y (1993) Detection of K-ras mutation in
sputum by mutant-allele-specific amplification (MASA). Hum Mutat
2(2): 112–117
Thiede C, Bayerdorffer E, Blasczyk R, Wittig B, Neubauer A (1996)
Simple and sensitive detection of mutations in the ras proto-
oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res
24(5): 983–984
Weber JL (1990) Human DNA polymorphisms and methods of analysis.
Curr Opin Biotechnol 1: 166–171
Wenger FA, Zieren J, Peter FJ, Jacobi CA, Muller JM (1999) K-ras mutations
in tissue and stool samples from patients with pancreatic cancer and
chronic pancreatitis. Langenbecks Arch Surg 384(2): 181–186
Wong T, Howes N, Threadgold J, Smart HL, Lombard MG, Gilmore I,
Sutton R, Greenhalf W, Ellis I, Neoptolemos JP (2001) Molecular
diagnosis of early pancreatic ductal adenocarcinoma in high-risk
patients. Pancreatology 1(5): 486–509
Ki-ras mutations in pancreatic cancer patients
JD a ¨britz et al
412
British Journal of Cancer (2005) 92(2), 405–412 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s